Cardiex Ltd
ASX:CDX

Watchlist Manager
Cardiex Ltd Logo
Cardiex Ltd
ASX:CDX
Watchlist
Price: 0.03 AUD
Market Cap: 16.5m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CDX stock under the Base Case scenario is 0.3 AUD. Compared to the current market price of 0.03 AUD, Cardiex Ltd is Undervalued by 90%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CDX Relative Value
Base Case
0.3 AUD
Undervaluation 90%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.2
P/S
P/S
Price to Sales
5.2
vs History
66
vs Industry
11
Median 3Y
13.7
Median 5Y
32.3
Industry
2.4
Forward
1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-11.5
Industry
22.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
50
Median 3Y
-5.5
Median 5Y
-15.9
Industry
14.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
40
Median 3Y
-6.6
Median 5Y
-15.4
Industry
20.9
More Details
2.5
P/B
P/B
Price to Book Value
2.5
vs History
87
vs Industry
13
Median 3Y
11
Median 5Y
22.3
Industry
2.3
More Details
4.8
EV/S
EV/S
Enterprise Value to Sales
4.8
vs History
65
vs Industry
11
Median 3Y
12.7
Median 5Y
32.4
Industry
2.6
Forward
0.9
More Details
6.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.6
vs History
63
vs Industry
13
Median 3Y
15.6
Median 5Y
41.7
Industry
5.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-12.8
Industry
11.9
Forward
-5.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-12.8
Industry
16.4
Forward
-5.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
51
Median 3Y
-5.2
Median 5Y
-15.9
Industry
14.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
41
Median 3Y
-5.1
Median 5Y
-15.2
Industry
18.1
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
96
vs Industry
22
Median 3Y
12.5
Median 5Y
17.9
Industry
1.9
More Details

Multiples Across Competitors

CDX Competitors Multiples
Cardiex Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Cardiex Ltd
ASX:CDX
16.5m AUD 5.2 -1.1 -1.2 -1.2
US
Abbott Laboratories
NYSE:ABT
230.8B USD 5.4 16.5 21.8 30.7
US
Intuitive Surgical Inc
NASDAQ:ISRG
169B USD 18.5 64.8 50.4 60.5
US
Boston Scientific Corp
NYSE:BSX
156.6B USD 8.5 62.5 35 48.3
US
Stryker Corp
NYSE:SYK
149.2B USD 6.3 51.1 25.3 30.5
IE
Medtronic PLC
NYSE:MDT
118.2B USD 3.5 25.4 13.9 20
DE
Siemens Healthineers AG
XETRA:SHL
53.3B EUR 2.3 24.5 13.8 19.3
US
Becton Dickinson and Co
NYSE:BDX
55.7B USD 2.6 34.7 13.3 24
US
IDEXX Laboratories Inc
NASDAQ:IDXX
51.5B USD 12.8 52.2 37.6 41.7
US
Edwards Lifesciences Corp
NYSE:EW
47.5B USD 8.4 11.5 25.4 27.8
US
Resmed Inc
NYSE:RMD
42.4B USD 8.2 30.3 21.8 24.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Cardiex Ltd
ASX:CDX
Average EV/EBITDA: 25.8
Negative Multiple: -1.2 		N/A N/A
US
Abbott Laboratories
NYSE:ABT
21.8
13%
1.7
US
Intuitive Surgical Inc
NASDAQ:ISRG
50.4
25%
2
US
Boston Scientific Corp
NYSE:BSX
35
22%
1.6
US
Stryker Corp
NYSE:SYK
25.3
12%
2.1
IE
Medtronic PLC
NYSE:MDT
13.9
7%
2
DE
Siemens Healthineers AG
XETRA:SHL
13.8
14%
1
US
Becton Dickinson and Co
NYSE:BDX
13.3
11%
1.2
US
IDEXX Laboratories Inc
NASDAQ:IDXX
37.6
12%
3.1
US
Edwards Lifesciences Corp
NYSE:EW
25.4
12%
2.1
US
Resmed Inc
NYSE:RMD
21.8
10%
2.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Cardiex Ltd
ASX:CDX
Average EV/EBIT: 32.8
Negative Multiple: -1.2 		N/A N/A
US
Abbott Laboratories
NYSE:ABT
30.7
23%
1.3
US
Intuitive Surgical Inc
NASDAQ:ISRG
60.5
27%
2.2
US
Boston Scientific Corp
NYSE:BSX
48.3
33%
1.5
US
Stryker Corp
NYSE:SYK
30.5
16%
1.9
IE
Medtronic PLC
NYSE:MDT
20
16%
1.2
DE
Siemens Healthineers AG
XETRA:SHL
19.3
19%
1
US
Becton Dickinson and Co
NYSE:BDX
24
27%
0.9
US
IDEXX Laboratories Inc
NASDAQ:IDXX
41.7
13%
3.2
US
Edwards Lifesciences Corp
NYSE:EW
27.8
13%
2.1
US
Resmed Inc
NYSE:RMD
24.8
12%
2.1

See Also

Summary
CDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
CDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CDX stock valuation using valuation multiples.
Wall Street Estimates
CDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 277,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.